恩瑞格的注意事项有什么？

(Deferasirox) is an oral iron chelator that was approved by the FDA in 2005 for the treatment of chronic iron overload caused by blood transfusions. The original research was by Novartis Pharmaceuticals. In January 2013, the FDA approved expanded indications to treat chronic iron overdose caused by Non-Transfusion Dependent Thalassemia Syndromes (NTDT), making Exjade the first drug to treat this indication. NTDT is a mild form of thalassemia that does not require frequent blood transfusions. However, even if patients do not receive blood transfusions, they will accumulate excess iron and damage various tissues and organs. Currently, deferasirox has been approved in more than 100 countries around the world for the treatment of transfusion-induced iron overload in children over 2 years of age. In China, only Deferasirox, the original product of Novartis Pharmaceuticals, was launched in June 2010, and only Jiangsu Aosaikang Pharmaceutical is applying for a domestically produced generic version.

So what should Enrig pay attention to?

Myelosuppression: Cytopenias (including agranulocytosis, neutropenia, thrombocytopenia, and worsening anemia) (some fatal) have been reported; patients with preexisting hematological disorders may be at increased risk; monitor blood counts regularly. Interrupt treatment in patients who develop cytopenia; may restart once cause of cytopenia is determined; contraindicated if platelet count <50,000/mm3.

Skin Toxicity: May cause rash (dose related); mild to moderate rash may resolve without interruption of treatment; for severe rash, interrupt and consider restarting with dose escalation and lower doses of oral steroids. Serious skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme have also been reported; the risk of other skin reactions including drug reactions with eosinophilia and systemic symptoms cannot be excluded.